All In Biotech

Drug Trial Radar · NCT07948733

First in Human Study of a Dual Targeting CD20 and CD19 CAR T Cell Treatment for Patients With B Cell Blood Cancers That Have Returned or Not Responded to Treatment

Phase I Clinical Trial of CD20/19 Chimeric Antigen Receptor CAR T Cells in Patients With Relapsed or Refractory Acute Lymphoblastic Leukaemia or Lymphoma

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

Oct 26, 2026

Primary completion

Sep 14, 2028

Study completion Sep 14, 2028

Sponsor

Sponsor type
Industry
Collaborators
Christian Medical College, Vellore, India
First posted
Nov 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

XenCART is an autologous bispecific CD20 and CD19 CAR T cell product from Cellogen Therapeutics Pvt Ltd. This first in human Phase I study at CMC Vellore will evaluate its safety tolerability and preliminary efficacy in adults with relapsed or refractory CD19 and CD20 positive B cell malignancies including B NHL and B ALL. Patients will undergo leukapheresis 9 to 12 day manufacturing fludarabine and cyclophosphamide lymphodepletion and a single intravenous infusion. The study includes a 28 day DLT evaluation period 24 months of active follow up and long term follow up thereafter. A 3 plus 3 dose escalation design with DSMB review after each cohort will evaluate sequential dose levels of 1 2 and 4 x 10 to the power 6 CAR T cells per kg to determine the recommended Phase II dose. Dual antigen targeting is expected to reduce CD19 negative relapse which is a major limitation of single target CAR T therapy. The study will establish the safety profile of XenCART and support its further development in India.

Conditions

  • B-Cell Non-Hodgkin Lymphoma (NHL)
  • B-cell Acute Lymphoblastic Leukemia (B-ALL)

Interventions

  • Autologous bispecific CD20/CD19 CAR-T cells - 1 × 10⁶ cells/kgBiological

    All patients receive lymphodepletion with cyclophosphamide 40 mg/kg IV on Day -5 and fludarabine 30 mg/m²/day IV from Day -5 to Day -2, followed by a single IV infusion of autologous bispecific CD20/CD19 CAR-T cells (XenCART; bicartigenlecleucel) at a dose of 1 × 10⁶ CAR-T cells/kg on Day 0. Dose may vary by ±20% due to manufacturing constraints.

  • Autologous bispecific CD20/CD19 CAR-T cells - 2 × 10⁶ cells/kgBiological

    All patients receive lymphodepletion with cyclophosphamide 40 mg/kg IV on Day -5 and fludarabine 30 mg/m²/day IV from Day -5 to Day -2, followed by a single IV infusion of autologous bispecific CD20/CD19 CAR-T cells (XenCART; bicartigenlecleucel) at a dose of 2 × 10⁶ CAR-T cells/kg on Day 0. Dose may vary by ±20% due to manufacturing constraints.

  • Autologous bispecific CD20/CD19 CAR-T cells - 4 × 10⁶ cells/kgBiological

    All patients receive lymphodepletion with cyclophosphamide 40 mg/kg IV on Day -5 and fludarabine 30 mg/m²/day IV from Day -5 to Day -2, followed by a single IV infusion of autologous bispecific CD20/CD19 CAR-T cells (XenCART; bicartigenlecleucel) at a dose of 4 × 10⁶ CAR-T cells/kg on Day 0. Dose may vary by ±20% due to manufacturing constraints.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose-limiting toxicities (DLT)Time frame: Day 0 (infusion) to Day +28
  2. Incidence and maximum grade of cytokine release syndrome (CRS)Time frame: Day 0 to Day +28
  3. Incidence and maximum grade of ICANSTime frame: Day 0 to Day +28
  4. Incidence and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)Time frame: Day 0 to Month 24
  5. Maximum tolerated dose (MTD) / recommended Phase 2 dose (RP2D)Time frame: Day 0 to Day +28 of the last evaluable participant in each cohort

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Haematology A Block 5th Floor Ranipet Campus Kilminnal Village Christian Medical College Vellore Ranipet Campus

    Vellore, Tamil Nadu, India · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.